Target intelligence / Profile preview

LYR motif-containing protein 4 (LYRM4)

Target
LYRM4
Molecular classification
Other (accessory protein for iron–sulfur cluster assembly, mitochondrial chaperone), Iron–sulfur cluster assembly factor
01

Overview

LYR motif-containing protein 4 (LYRM4, also known as ISD11) is an essential mitochondrial accessory protein required for the assembly of iron–sulfur (Fe–S) clusters, which are vital cofactors for numerous enzymes in energy metabolism, DNA repair, and cellular respiration. LYRM4 forms part of the mitochondrial cysteine desulfurase complex (with NFS1 and ACP), stabilizing NFS1 and modulating its cysteine desulfurase activity to enable sulfur transfer onto the ISCU scaffold protein and subsequent Fe–S cluster formation. LYRM4 is crucial for mitochondrial function and overall cellular iron homeostasis, and its dysfunction or altered expression is implicated in mitochondrial disorders and cancer, particularly liver hepatocellular carcinoma. Increased expression of LYRM4 correlates with poor prognosis in some cancers, and it may act as a potential biomarker for tumor progression and metabolic reprogramming.

Other names
LYR motif containing 4LYRM4ISD11C6orf149CGI-203COXPD19mitochondrial matrix Nfs1 interacting proteinhomolog of yeast Isd11
02

Mechanism of action

Not directly drug-targeted; as an accessory protein, dysfunction or modulation could affect therapies targeting mitochondrial function, iron-sulfur metabolism, or redox biology.

03

Biological functions

Iron–sulfur cluster (Fe–S cluster) biogenesisRegulation of mitochondrial respirationRegulation of tricarboxylic acid cycle and oxidative phosphorylationCellular iron homeostasisMitochondrial function maintenance
04

Disease associations

Cancer (notably liver hepatocellular carcinoma)Mitochondrial disorders (e.g., Combined Oxidative Phosphorylation Deficiency 19)Leigh diseaseDisruption leads to disorders of mitochondrial and cytosolic iron homeostasis, and neurological disease
05

Safety considerations

Dysregulation or inhibition could disrupt mitochondrial Fe–S protein assembly, leading to electron transport chain defects, mitochondrial dysfunction, and metabolic diseasePotential to affect energy metabolism in normal tissues
06

Biomarkers

LYRM4 mRNA/protein expression (prognostic and diagnostic biomarker in liver hepatocellular carcinoma)Co-expression with PRIM2, NFU1, or POLD1 as a combined biomarker panel for early diagnosis of liver cancer

Beyond the preview

Go deeper on LYR motif-containing protein 4 (LYRM4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYR motif-containing protein 4 (LYRM4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call